通过中断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与血管紧张素转换酶2(ACE2)之间的相互作用来实现SARS-CoV-2早期进入的潜在治疗方法。

Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).

作者信息

Xiang Yusen, Wang Mengge, Chen Hongzhuan, Chen Lili

机构信息

Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

出版信息

Biochem Pharmacol. 2021 Oct;192:114724. doi: 10.1016/j.bcp.2021.114724. Epub 2021 Aug 8.

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread around the globe. At present, there is no precise and effective treatment for the patients with COVID-19, so rapid development of drugs is urgently needed in order to contain the highly infectious disease. The virus spike protein (S protein) can recognize the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell membrane and undergo a series of conformational changes, protease cleavage and membrane fusion to complete the virus entry, so S protein is an important target for vaccine and drug development. Here we provide a brief overview of molecular mechanisms of virus entry, as well as some potential antiviral agents that act on S/ACE2 protein-protein interaction. Specifically, we focused on experimentally validated and/or computational prediction identified inhibitors that target SARS-CoV-2 S protein, ACE2 and enzymes associated with viral infection. This review offers valuable information for the discovery and development of potential antiviral agents in combating SARS-CoV-2. In addition, with the deepening understanding of the mechanism of SARS-CoV-2 infection, more targeted prevention and treatment drugs will be explored with the aid of the advanced technology in the future.

摘要

由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新型冠状病毒肺炎疫情已在全球迅速蔓延。目前,对于新型冠状病毒肺炎患者尚无精确有效的治疗方法,因此迫切需要快速研发药物以控制这种高传染性疾病。病毒刺突蛋白(S蛋白)可识别宿主细胞膜上的血管紧张素转换酶2(ACE2)受体,并经历一系列构象变化、蛋白酶切割和膜融合以完成病毒进入过程,所以S蛋白是疫苗和药物研发的重要靶点。在此,我们简要概述病毒进入的分子机制,以及一些作用于S/ACE2蛋白-蛋白相互作用的潜在抗病毒药物。具体而言,我们重点关注经实验验证和/或通过计算预测确定的靶向严重急性呼吸综合征冠状病毒2 S蛋白、ACE2以及与病毒感染相关酶的抑制剂。本综述为发现和开发对抗严重急性呼吸综合征冠状病毒2的潜在抗病毒药物提供了有价值的信息。此外,随着对严重急性呼吸综合征冠状病毒2感染机制的深入了解,未来借助先进技术将探索出更多靶向性的预防和治疗药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1437/8349388/9254a202d1b4/ga1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索